Novavax (NVAX) Gross Margin (2011 - 2026)

Novavax's Gross Margin history runs 11 years deep, the most recent figure standing at 78.0% for Q1 2026.

• In Q1 2026, Gross Margin fell 1988.0% year-over-year to 78.0%; the TTM figure through Mar 2026 stood at 83.16% (down 428.0% YoY), while the FY2025 annual figure was 93.5%, up 2322.0% from the prior year.
• Gross Margin was 78.0% for Q1 2026 at Novavax, down from 84.98% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 97.88% in Q1 2025 to a low of 45.8% in Q2 2022.
• Historically, Gross Margin has averaged 59.69% across 5 years, with a median of 58.48% in 2024.
• The sharpest annual moves came in 2022 and 2023: Gross Margin sank 14580 bps in 2022, then surged 13266 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 49.14% in 2022, then decreased by 5 bps to 46.81% in 2023, then climbed by 25 bps to 58.48% in 2024, then jumped by 45 bps to 84.98% in 2025, then declined by 8 bps to 78.0% in 2026.
• The last three Gross Margin figures came in at 78.0% (Q1 2026), 84.98% (Q4 2025), and 69.49% (Q3 2025), per Business Quant data.